Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed sentiment. While there are positive developments like the expected growth of Buvidal and Brixadi, there are concerns about funding challenges, unclear management responses, and reliance on external policy changes. The Q&A section highlights uncertainties, particularly in the U.K. and Germany, which may limit positive market reactions. The guidance remains stable but lacks significant upward momentum, resulting in a neutral outlook.
Key Financial Performance
Full Year Revenue 2025 SEK 2.3 billion, a 21% growth year-over-year (30% at constant exchange rates). Growth driven by increased product sales and Brixadi royalty income.
Profit Before Tax 2025 SEK 0.9 billion, an 86% increase year-over-year. Growth attributed to strong product sales and royalty income despite significant R&D investments and U.S. expansion.
Quarterly Revenue Q4 2025 SEK 464 million, a 16% decline year-over-year. Decline due to changes in the U.K. distribution model and FX headwinds.
Quarterly Product Sales Q4 2025 SEK 342 million, a 27% decrease year-over-year. Decrease primarily due to the change in the U.K. distribution model.
Quarterly Royalty Income from Brixadi Q4 2025 SEK 122 million, a 47% increase year-over-year (82% at constant exchange rates). Growth driven by strong U.S. market performance.
Full Year Product Sales 2025 Increased by 6% year-over-year. Growth supported by Buvidal and Brixadi sales.
Full Year Brixadi Royalty Income 2025 Increased by 87% year-over-year. Growth driven by strong market penetration in the U.S.
Marketing and Distribution Expenses Q4 2025 Decreased by 12% year-over-year. Reduction attributed to operational efficiencies.
Marketing and Distribution Expenses Full Year 2025 Increased by 7% year-over-year. Increase driven by commercial rollout of Buvidal in Europe and Australia and U.S. expansion.
R&D Costs Q4 2025 Decreased by 20%-25% year-over-year. Reduction due to completion of clinical trials for CAM2029 and CAM2056.
R&D Costs Full Year 2025 Decreased by 24% year-over-year. Reduction due to completion of clinical trials and deferral of some costs to 2026.
Operating Result Q4 2025 SEK 113 million, a 32% decrease year-over-year. Decline due to reduced revenue and increased costs.
Operating Result Full Year 2025 SEK 874 million, an 86% increase year-over-year. Growth driven by Buvidal sales and Brixadi royalty income.
Cash Position Q4 2025 SEK 3.7 billion, a 30% increase year-over-year. Increase driven by operating activities and changes in working capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Oczyesa approval: Oczyesa received regulatory approval for acromegaly in both EU and the U.K. and was launched in Germany, marking the first European country to introduce this product.
Oclaiz resubmission: The NDA for Oclaiz was resubmitted to the FDA and accepted with a PDUFA date in June 2026.
CAM2056 Phase Ib results: Reported compelling Phase Ib results for CAM2056, showing faster and greater reductions in body weight and blood glucose compared to weekly semaglutide.
U.S. market expansion: Commercial infrastructure established in the U.S. to support upcoming product launches, including Oclaiz.
Buvidal market growth: Buvidal maintained leadership in the long-acting buprenorphine segment in Australia and the Nordics, with significant growth opportunities in larger European markets.
Brixadi U.S. performance: Brixadi royalties in the U.S. grew 47% year-on-year, capturing at least 30% of the long-acting buprenorphine segment.
Revenue growth: Full year revenue reached SEK 2.27 billion, a 21% growth from 2024.
Cost management: R&D costs reduced by 24% for the full year, while marketing and distribution expenses increased by 7% due to U.S. expansion.
Cash position: Net cash position increased by SEK 3.7 billion, a 30% rise from the previous year.
Lilly partnership: Entered a strategic license agreement with Lilly for long-acting incretin therapy.
Policy advocacy: Efforts in the U.K., France, Germany, and Spain to improve access to Buvidal, including removal of restrictions in Spain.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Buvidal sales decline: Temporary decline in Buvidal sales due to FX headwinds and changes in the U.K. distribution model, leading to a 27% decrease in quarterly product sales.
U.K. distribution model change: The change in the U.K. distribution model caused a repurchase of SEK 93 million worth of inventory, impacting financial performance.
Market access challenges: Access and funding hurdles in larger European markets like England, France, and Germany limit Buvidal's penetration and growth potential.
Physician remuneration in Germany: Challenges in Germany due to physician remuneration issues, slowing access to innovative treatments like Buvidal.
Macroeconomic uncertainties: Current macroeconomic uncertainties are highlighted as a key consideration for 2026 financial guidance, potentially impacting market dynamics and pricing conditions.
Increased operating expenses: Expected increase in operating expenses due to organizational expansion and increased R&D activities, including an additional SEK 200 million for U.S. operations and SEK 150 million for R&D.
Regulatory and reimbursement risks: Potential risks related to clinical progress, regulatory outcomes, and reimbursement landscapes, which are critical for product launches and market access.
Slow progress in policy changes: Slow progress in policy changes in markets like Germany, where stakeholder support exists but implementation is delayed, affecting access to treatments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Revenue is expected to be in the range of SEK 2.6 billion to SEK 2.9 billion, representing an approximate 21% increase from 2025.
Operating Result Guidance for 2026: Operating result is projected to be between SEK 0.9 billion and SEK 1.2 billion, reflecting an approximate 20% increase.
R&D Expenses for 2026: R&D expenses are expected to increase by approximately SEK 150 million due to new trials and ongoing projects.
U.S. Operations Expansion: An additional SEK 200 million will be allocated to expanding U.S. operations in preparation for the planned Oclaiz launch in mid-2026.
Buvidal Growth Expectations: Continued growth is expected in 2026, particularly in larger European markets where access and funding issues are being addressed. Double-digit growth is anticipated.
Brixadi Market Penetration: Continued market penetration is expected in 2026, focusing on converting patients from daily sublingual buprenorphine and improving access in the criminal justice setting.
Oczyesa Launch in Europe: The European launch of Oczyesa has begun, with positive initial feedback. Further launches are planned in the U.K. and Norway.
Oclaiz U.S. Launch: Pending FDA approval, Oclaiz is planned for a U.S. launch in mid-2026, with preparations including market access, advocacy, and distribution plans.
SORENTO Study for GEP-NET: The Phase III SORENTO study is on track for primary efficacy results in the second half of 2026, representing a significant commercial opportunity with global peak sales estimated at USD 2 billion.
CAM2056 Development: A Phase IIb study for CAM2056 is planned to begin in the second half of 2026, following promising Phase Ib results.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: Camurus repurchased SEK 93 million worth of inventory from its U.K. wholesaler due to a change in the U.K. distribution model.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the core component phase of the SORENTO trial, and is the top-line data still estimated for mid to late 2026?
A:The core phase refers to the randomized part of the study, up to the point where data can start being read out. The top-line data is still estimated for mid to late 2026.
Q:Can you provide more details on the new auto-injector pen device for CAM2056?
A:The auto-injector is a new device specifically developed for CAM2056, and the company has been working on it for quite some time.
Q:What is the FX impact in the U.S., and why is there a 35% headwind when the USD to SEK headwind is 17%?
A:The FX impact is due to fluctuations in currencies, particularly the Australian dollar and U.S. dollar. The 35% headwind arises from technical factors like the timing of invoice bookings and a decrease in currency values over the year.
Q:Have the 2027 goals changed based on 2025 performance, and are you still targeting a 50% EBIT margin?
A:The 2027 goals remain unchanged, including the 50% EBIT margin target. The company maintains its vision for 2027 despite challenges.
Q:Does the guidance range reflect concerns about ongoing FX headwinds?
A:Yes, the guidance range accounts for currency exchange risks, with thorough analysis of expectations for currency development. The company is exposed to the U.S. dollar but has a more natural hedge due to increasing U.S. expenses.
Q:Is the milestone from Braeburn in 2026 included in guidance, and what is its size?
A:The milestone is expected in 2026 but was not realized in 2025. The size is the smallest of three milestones, with a total amount of $75 million.
Q:When is the SORENTO trial likely to be completed in the second half of 2026?
A:There is uncertainty about the exact timing as it depends on accrual rates and is an event-driven trial. More updates are expected in early 2026.
Q:What caused the 25% dip in Buvidal revenue per patient over the last 9 months?
A:The dip is attributed to country mix and FX impact, while prices remain stable across markets.
Q:What is the status of Buvidal in the U.K., Germany, and France?
A:In Germany, there is growing momentum for remuneration reform. In the U.K., Wales and Scotland have high penetration, while England faces funding challenges. France has ongoing discussions for funding allocation.
Q:Are there specific events that remain for policy changes in Germany, U.K., and France?
A:Policy changes are difficult to predict as they involve external stakeholders. The company is not directly involved in remuneration discussions.
Q:Is there any distributor stock left in the U.K. that could impact 2026 sales?
A:No, there is no more stock in the channel.
Q:What does the guidance mean by pricing conditions and reimbursement impacting guidance?
A:The guidance is based on the current understanding of pricing and reimbursement landscapes, which are relatively stable. Competitive developments in the U.S. are also considered.
Q:Does FluidCrystal enhance bioavailability, and what are the key changes in the Phase IIb trial for semaglutide?
A:FluidCrystal showed the same Cmax concentration at a much higher dose compared to the approved product. The Phase IIb trial will be longer and controlled, focusing on weight reduction and dosing mechanisms.
Q:What are the expected contributions from Buvidal, Brixadi, and Oczyesa in 2026 guidance?
A:Buvidal is expected to grow at a similar rate to 2025. Brixadi is expected to perform well in the U.S., while Oczyesa's contribution will be low as it is early in the launch cycle.
Q:How will the 100,000 patient target for Buvidal by 2027 be achieved?
A:The target relies on solving funding challenges and improving access in key European markets. Growth is expected from new markets and increased penetration in existing ones.
Q:What proportion of Buvidal sales comes from the U.K.?
A:The company has not disclosed the proportion of sales from the U.K.
Q:Where are the German patients for Buvidal coming from?
A:Patients are a mix from criminal justice settings and community settings, including those more open to prescribing long-acting treatments.
Q:When will Oczyesa launch in France, Spain, and Italy?
A:France is expected to launch at the earliest in 2027, with other markets following later.
Q:What is the communication frequency with Eli Lilly, and are they satisfied with the data?
A:The company cannot disclose details about the collaboration with Eli Lilly.
Q:What is the shelf life of inventory in the U.K., and can it be reallocated?
A:The shelf life is 36 months, and the inventory can be reallocated to other geographies.
Q:Will the Phase III trial for PLD start in 2026, and is it included in guidance?
A:The Phase III trial could start in 2026 if alignment with the agency is achieved. The costs are included in the current financial expectations.
Q:Is the 100,000 patient target for Buvidal back-end loaded?
A:The target may be back-end loaded as reimbursement hurdles are removed, but some areas are in advanced discussions that could accelerate growth.
Q:What is the composition of the SEK 4.5 billion revenue target for 2027?
A:The composition includes SEK 2.6 billion from Buvidal and SEK 1.9 billion from the pipeline, with some uncertainty due to delays in SORENTO and other factors.
Q:Why was the distribution model in the U.K. changed?
A:The change was due to volatility in the U.K. market, alignment with global distribution strategy, and upcoming Oczyesa launch.
Q:Are the 20 Oczyesa patients in Germany switch patients or naive patients?
A:They are switch patients from both Sandostatin and Somatuline.
Q:Will Brixadi experience a similar Q1 dip in 2026 as in 2025?
A:The dynamics from COVID-related changes are no longer present, so a similar dip is not expected.
Q:Will the Phase III trial for PLD start in 2026, and is it included in guidance?
A:The trial could start in 2026 if alignment with the agency is achieved. Costs are included in the guidance.
Q:What is the funding situation for Buvidal in the U.K.?
A:NHS England funding for prisons is in place, while community-based funding has been slow to reach clinics. New funding is expected from April 2026.
Q:What are the M&A and BD priorities for 2026?
A:The focus is on pre-commercial and commercial assets in endocrinology, rare oncology, rare diseases, and CNS, with an emphasis on late-stage opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size of the Braeburn milestone, the exact timing of SORENTO trial completion, and the proportion of Buvidal sales from the U.K. They also did not disclose the frequency of communication with Eli Lilly or whether Eli Lilly is satisfied with the data. Additionally, they did not provide clarity on the timing of funding reaching clinics in the U.K. or specific events for policy changes in Germany, U.K., and France.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anders
Australia
Brixadi royalty
Camurus
France
Germany
NDA
Nordics
Oclaiz
RD
SEK increase
Spain
UK distribution
access
buprenorphine
challenge
change UK
country
distribution model
exchange rate
expansion
funding
launch
market penetration
milestone
patient treatment
physician
policy
product
progress
reduction
result
royalty income
sale SEK
segment
setting
CTGO Transcript
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Unknown2-13
The earnings call summary presents a mixed sentiment. While there are positive developments like the expected growth of Buvidal and Brixadi, there are concerns about funding challenges, unclear management responses, and reliance on external policy changes. The Q&A section highlights uncertainties, particularly in the U.K. and Germany, which may limit positive market reactions. The guidance remains stable but lacks significant upward momentum, resulting in a neutral outlook.
Contango Ore, Inc. (CTGO) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call lacked detailed financial performance metrics, which makes it difficult to assess the company's current financial health. The Q&A highlighted operational efficiency and strategic focus on projects, but management's avoidance of specific details on certain topics may raise concerns. The absence of a Q3 earnings presentation and unclear management responses further contribute to the neutral sentiment. However, there are no significant negative indicators, and the company's strategic initiatives and operational updates suggest stability, leading to a neutral prediction for stock price movement.
Contango Ore, Inc. (CTGO) Q2 2025 Earnings Call Transcript
Positive8-14
The earnings call summary and Q&A reveal a positive sentiment, driven by strong operating income, effective cost management, and strategic debt reduction. The company's hedging strategy and production consistency further support this outlook. Despite some uncertainties, such as the Beluga whale lawsuit and the monetization of Onyx shares, the overall performance and future plans, including project advancements and potential shareholder rewards, indicate a positive trajectory for the stock price over the next two weeks.
Contango Ore (CTGO) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call highlights several financial risks, including increased ASIC, significant debt, and liquidity concerns from trade payables. Despite a positive project dismissal and potential for extended mine life, the financial health remains precarious. The Q&A reveals management's vague responses about hedging and securities, adding uncertainty. The lack of a share repurchase program and a net loss further dampen sentiment. While there are positive elements like reduced debt and valuable investments, the overall financial outlook and management's unclear communication contribute to a negative sentiment.
CTGO Slides
CTGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
